| Identification | Back Directory | [Name]
2-[(4-methylquinazolin-2-yl)amino]-6-{[(1-phenyl-1H-tetrazol-5-yl)sulfanyl]methyl}pyrimidin-4(1H)-one | [CAS]
673443-80-6 | [Synonyms]
DCE254
DCE-254
DCE 254
DCE_254
4(3H)-Pyrimidinone, 2-[(4-methyl-2-quinazolinyl)amino]-6-[[(1-phenyl-1H-tetrazol-5-yl)thio]methyl]-
2-[(4-methylquinazolin-2-yl)amino]-6-{[(1-phenyl-1H-tetrazol-5-yl)sulfanyl]methyl}pyrimidin-4(1H)-one | [Molecular Formula]
C21H17N9OS | [MOL File]
673443-80-6.mol | [Molecular Weight]
443.48 |
| Hazard Information | Back Directory | [Description]
DCE_254 is a novel EZH2 inhibitor that also displays significant anti-proliferation activity against lymphoma cell lines. | [Uses]
DCE_254 is an EZH2 inhibitor (IC50=11 μM) that also exhibits significant antiproliferative activity against lymphoma cell lines. DCE_254 inhibits the development of hypermethylation-related cancers by inhibiting the SAM-mediated methyl transfer process (IC50=10.3 μM)[1]. | [References]
[1] Wu Y, et al. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays[J]. Bioorganic & Medicinal Chemistry Letters, 2016, 26(15): 3813-3817. DOI:10.1016/j.bmcl.2016.05.018 |
|
| Company Name: |
Specs
|
| Tel: |
+31 15 251 8111 |
| Website: |
www.specs.net |
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|